Inventor
Liying Zhou
Inventor
CN
Overview
Patents· 18 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes28%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations28%
C07DHeterocyclic compounds23%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium10%
C07BGeneral methods of organic chemistry3%
C12NMicroorganisms or enzymes3%
C07CAcyclic or carbocyclic compounds2%
H04BTransmission2%
H04LTransmission of digital information, e.g. telegraphic communication2%
PatentTitleYear
12,595,261P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition containing same, and use thereof202612,582,653Method for treating idiopathic pulmonary fibrosis202612,544,3822, 4, 6-tri-substituted pyrimidine compound as ATR kinase inhibitor202612,509,479P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof202512,485,108Method for treating fatty liver disease and/or steatohepatitis202512,459,917Salt of diaminopyrimidine compounds, and solid form thereof, preparation method therefor and use thereof202512,398,118Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and use thereof202512,365,665Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereof202512,255,721Method performed by a base station, base station and computer-readable storage medium202512,180,243Receptor inhibitor, pharmaceutical composition comprising same, and use thereof202411,938,222Pregabalin sustained release composition and method for preparing the same202411,939,578Double-stranded RNA molecule targeting CKIP-1 and use thereof202411,919,918P2X3 andor P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof202411,905,274Receptor inhibitors, pharmaceutical compositions comprising the same and use thereof202411,453,690Receptor inhibitor, pharmaceutical composition comprising same, and use thereof202211,414,444P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof202211,390,609Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof202211,155,819Double-stranded RNA molecule targeting CKIP-1 and use thereof2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2026Patents assigned to BEIJING TIDE PHARMACEUTICAL CO LTD (17)· patent assignee history
2021–2026Based in CN· patent location history
2025Patents assigned to SAMSUNG ELECTRONICS CO LTD (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| BEIJING TIDE PHARMACEUTICAL CO LTD | 17 | 2021–2026 |
| SAMSUNG ELECTRONICS CO LTD | 1 | 2025 |
Locations
| Location | Patents | Span |
|---|---|---|
| CN | 18 | 2021–2026 |